Does the media prefer RVMD or ARWR?

In the previous week, Revolution Medicines had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 8 mentions for Revolution Medicines and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.86 beat Revolution Medicines' score of 0.34 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ONC or ARWR?

In the previous week, BeOne Medicines had 7 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 13 mentions for BeOne Medicines and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.86 beat BeOne Medicines' score of 0.18 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRNA or ARWR?

In the previous week, Moderna had 17 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 23 mentions for Moderna and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.86 beat Moderna's score of 0.52 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Arrowhead Pharmaceuticals and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Arrowhead Pharmaceuticals' score of 0.86 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arrowhead Pharmaceuticals (ARWR) Competitors

$78.89 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$80.50 +1.61 (+2.04%)

As of 06/26/2026 07:47 PM Eastern

Compare

ARWR vs. TEVA, RVMD, ONC, MRNA, and BNTX

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? MarketBeat compares Arrowhead Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arrowhead Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), Moderna (MRNA), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 25.68%. Arrowhead Pharmaceuticals has a consensus price target of $86.36, indicating a potential upside of 9.47%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 6 mentions for Arrowhead Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.27 beat Arrowhead Pharmaceuticals' score of 0.86 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99
Arrowhead Pharmaceuticals	$829.45M	13.40	-$1.63M	-$2.15	N/A

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Arrowhead Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,342.85	-$1.13B	-$7.07	N/A
Arrowhead Pharmaceuticals	$829.45M	13.40	-$1.63M	-$2.15	N/A

Revolution Medicines presently has a consensus target price of $123.72, indicating a potential downside of 32.05%. Arrowhead Pharmaceuticals has a consensus target price of $86.36, indicating a potential upside of 9.47%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Revolution Medicines had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 8 mentions for Revolution Medicines and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.86 beat Revolution Medicines' score of 0.34 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

BeOne Medicines has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62
Arrowhead Pharmaceuticals	$829.45M	13.40	-$1.63M	-$2.15	N/A

BeOne Medicines currently has a consensus price target of $390.00, indicating a potential upside of 39.34%. Arrowhead Pharmaceuticals has a consensus price target of $86.36, indicating a potential upside of 9.47%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe BeOne Medicines is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

In the previous week, BeOne Medicines had 7 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 13 mentions for BeOne Medicines and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.86 beat BeOne Medicines' score of 0.18 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BeOne Medicines' return on equity of 12.06% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

BeOne Medicines beats Arrowhead Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Moderna had 17 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 23 mentions for Moderna and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.86 beat Moderna's score of 0.52 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Moderna presently has a consensus price target of $37.13, suggesting a potential downside of 44.80%. Arrowhead Pharmaceuticals has a consensus price target of $86.36, suggesting a potential upside of 9.47%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Moderna. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A
Arrowhead Pharmaceuticals	$829.45M	13.40	-$1.63M	-$2.15	N/A

75.3% of Moderna shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Arrowhead Pharmaceuticals beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A
Arrowhead Pharmaceuticals	$829.45M	13.40	-$1.63M	-$2.15	N/A

BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioNTech currently has a consensus price target of $129.56, suggesting a potential upside of 42.03%. Arrowhead Pharmaceuticals has a consensus price target of $86.36, suggesting a potential upside of 9.47%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Arrowhead Pharmaceuticals and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Arrowhead Pharmaceuticals' score of 0.86 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a net margin of -44.39% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BioNTech's return on equity of -5.30% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

BioNTech beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.11B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-36.69	21.75	26.14	24.17
Price / Sales	13.40	334.26	555.66	102.83
Price / Cash	660.72	62.10	29.09	36.93
Price / Book	21.67	8.31	10.78	6.38
Net Income	-$1.63M	$23.92M	$3.58B	$337.00M
7 Day Performance	-3.79%	1.93%	1.97%	-0.20%
1 Month Performance	1.26%	-0.41%	-0.24%	-1.40%
1 Year Performance	390.61%	65.22%	34.39%	27.76%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	2.0025 of 5 stars	$78.89 flat	$86.36 +9.5%	+390.6%	$11.11B	$829.45M	N/A	400	Analyst Upgrade High Trading Volume
TEVA Teva Pharmaceutical Industries	4.8566 of 5 stars	$32.25 +2.4%	$41.78 +29.6%	+98.4%	$36.20B	$17.26B	24.24	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6462 of 5 stars	$165.81 +1.7%	$123.72 -25.4%	+393.3%	$34.65B	$11.58M	N/A	250	Insider Trade Gap Down
ONC BeOne Medicines	4.7773 of 5 stars	$271.80 +0.6%	$390.00 +43.5%	+16.0%	$29.64B	$5.34B	60.81	12,000	News Coverage Analyst Upgrade Insider Trade
MRNA Moderna	1.1098 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+147.7%	$25.38B	$1.94B	N/A	4,700	Trending News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. TEVA, RVMD, ONC, MRNA, and BNTX

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Moderna?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. TEVA, RVMD, ONC, MRNA, and BNTX

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Do analysts recommend TEVA or ARWR?

Is TEVA or ARWR more profitable?

Does the media prefer TEVA or ARWR?

Do insiders and institutionals believe in TEVA or ARWR?

Which has higher valuation & earnings, TEVA or ARWR?

Which has more risk and volatility, TEVA or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Which has more volatility and risk, RVMD or ARWR?

Do institutionals & insiders believe in RVMD or ARWR?

Which has preferable earnings and valuation, RVMD or ARWR?

Do analysts recommend RVMD or ARWR?

Is RVMD or ARWR more profitable?

Does the media prefer RVMD or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Which has stronger valuation and earnings, ONC or ARWR?

Do analysts recommend ONC or ARWR?

Do institutionals and insiders believe in ONC or ARWR?

Which has more volatility & risk, ONC or ARWR?

Does the media prefer ONC or ARWR?

Is ONC or ARWR more profitable?

Summary

How does Arrowhead Pharmaceuticals compare to Moderna?

Does the media prefer MRNA or ARWR?

Which has more volatility and risk, MRNA or ARWR?

Is MRNA or ARWR more profitable?

Do analysts recommend MRNA or ARWR?

Which has higher valuation and earnings, MRNA or ARWR?

Do institutionals & insiders hold more shares of MRNA or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Which has preferable valuation and earnings, BNTX or ARWR?

Which has more risk & volatility, BNTX or ARWR?

Do insiders and institutionals hold more shares of BNTX or ARWR?

Do analysts rate BNTX or ARWR?

Does the media prefer BNTX or ARWR?

Is BNTX or ARWR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools